CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

August 17, 2026 · Phase 3 readout

ARGX Phase 3 readout: a positive outcome, +16.0%

On August 17, 2026, efgartigimod administration — argenx SE (Myasthaenia Gravis) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +16.0% in the window around the event.

The move

$851.29
1d before
$987.84
Event day
$992.99
1d after
$1039.78
5d after

Pre-catalyst setup

-1.1%
30-day run-up
4304%
30-day volatility
1.0×
volume spike